Please sign in to follow a disease.
Scientists hunt for better ways to diagnose and treat rare bone tumors
NCT ID NCT07315542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 300 people with cartilage tumors, including both benign types and the cancer chondrosarcoma. Researchers are studying genetic changes and molecules called miRNAs to better tell these tumors apart and predict outcomes. The goal is to improve diagnosis and find new treatment targets for hard-to-treat cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of patients with cartilaginous (chondroid) tumours treated at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno, a national referral centre for bone tumours.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Histologically confirmed cartilaginous (chondroid) tumour * Diagnosis includes one of the following entities (as available and eligible): * Enchondroma * Atypical cartilaginous tumour / Grade 1 chondrosarcoma (ACT/G1) * Conventional chondrosarcoma (Grade 2-3) * Dedifferentiated chondrosarcoma * Other rare chondrosarcoma variants (e.g., mesenchymal, clear-cell), if present in the cohort * Patients treated and/or followed at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno Exclusion Criteria * Insufficient, degraded, or otherwise unusable tissue samples
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cartilage tumours are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
RECRUITINGBrno, South Moravian, 60200, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- Experimental drug tested for rare cancer, trial stopped early
- Blood test could spot cartilage cancer early, without radiation
- New hope for rare bone cancer? drug shows promise in early trial
- Rare bone tumor under the microscope: can we predict its behavior?
- Proton beam therapy tested for rare spine and skull base tumors